ArticleStem cells (Dayton, Ohio)2010
B-Myb is critical for proper DNA duplication during an unperturbed S phase in mouse embryonic stem cells.
Article in Stem cells (Dayton, Ohio), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 56 citations in OpenAlex.
- Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma.Journal of experimental & clinical cancer research : CR · 2017Trial
- MYBL2 regulates the expression of CENPF in lung adenocarcinoma and promotes tumor development and metastasis through AKT pathway activation.European journal of medical research · 2025Article
- A-MYB substitutes for B-MYB in activating cell cycle genes and in stimulating proliferation.Nucleic acids research · 2024Article
- Molecular Regulation of Porcine Skeletal Muscle Development: Insights from Research on CDC23 Expression and Function.International journal of molecular sciences · 2024Article
- Robust discovery of gene regulatory networks from single-cell gene expression data by Causal Inference Using Composition of Transactions.Briefings in bioinformatics · 2023Article
- Interleukin-17 contributes to Ross River virus-induced arthritis and myositis.PLoS pathogens · 2022Article
- MYBL2 and ATM suppress replication stress in pluripotent stem cells.EMBO reports · 2021Article
- MYB oncoproteins: emerging players and potential therapeutic targets in human cancer.Oncogenesis · 2021Review
- CDCA8, targeted by MYBL2, promotes malignant progression and olaparib insensitivity in ovarian cancer.American journal of cancer research · 2021Article
- Mybl2 rejuvenates heart explant-derived cells from aged donors after myocardial infarction.Aging cell · 2020Article
- Characterization of the zinc finger proteins ZMYM2 and ZMYM4 as novel B-MYB binding proteins.Scientific reports · 2020Article
- Overexpression of MYBL2 promotes proliferation and migration of non-small-cell lung cancer via upregulating NCAPH.Molecular and cellular biochemistry · 2020Article
- Review
- In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors.Scientific reports · 2018Article
- Demethylzeylasteral inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axis.Cell death & disease · 2018Article
- CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.Endocrinology · 2018Article
- Fine-Tuning Mybl2 Is Required for Proper Mesenchymal-to-Epithelial Transition during Somatic Reprogramming.Cell reports · 2018Article
- Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place.Cancer discovery · 2018Review
- A novel microRNA, hsa-miR-6852 differentially regulated by Interleukin-27 induces necrosis in cervical cancer cells by downregulating the FoxM1 expression.Scientific reports · 2018Article
- MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis.Cell death & disease · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
A common feature of early embryo cells from the inner cell mass (ICM) and of ESCs is an absolute dependence on an atypical cell cycle in which the G1 phase is shortened to preserve their self-renewing and pluripotent nature. The transcription factor B-Myb has been attributed a role in proliferation, in particular during the G2/M phases of the cell cycle. Intriguingly, B-Myb levels in ICM/ESCs are greater than 100 times compared with those in normal proliferating cells, suggesting a particularly important function for this transcription factor in pluripotent stem cells. B-Myb is essential for embryo development beyond the preimplantation stage, but its role in ICM/ESCs remains unclear. Using a combination of mouse genetics, single DNA fiber analyses and high-resolution three-dimensional (3D) imaging, we demonstrate that B-Myb has no influence on the expression of pluripotency factors, but instead B-Myb ablation leads to stalling of replication forks and superactivation of replication factories that result in disorganization of the replication program and an increase in double-strand breaks. These effects are partly due to aberrant transcriptional regulation of cell cycle proliferation factors, namely c-Myc and FoxM1, which dictate normal S phase progression. We conclude that B-Myb acts crucially during the S phase in ESCs by facilitating proper progression of replication, thereby protecting the cells from genomic damage. Our findings have particular relevance in the light of the potential therapeutic application of ESCs and the need to maintain their genomic integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.